Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer

Journal of Chemotherapy

Volumn 24, Issue 4, 2012, Pages 221-225

  Del Fabbro, Egidio ^a   Dev, Rony ^a   Cabanillas, Maria E ^a   Busaidy, Naifa L ^a   Rodriguez, EdenMae C ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Extreme hypothyroidism; Sunitinib; Symptoms

Indexed keywords

BEVACIZUMAB; FUMARATE HYDRATASE; HEMOGLOBIN; LEVOTHYROXINE; SUNITINIB; THYROTROPIN; TREBANANIB;

ADULT; APPETITE; ARTICLE; BONE METASTASIS; CASE REPORT; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTHYROIDISM; INSOMNIA; KIDNEY METASTASIS; LEIOMYOMATOSIS; LIVER METASTASIS; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; THYROTROPIN BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; ANGIOGENESIS INHIBITORS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DRUG RESISTANCE; FATAL OUTCOME; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOTHYROIDISM; INDOLES; KIDNEY NEOPLASMS; LIVER NEOPLASMS; PYRROLES; SEVERITY OF ILLNESS INDEX; THYROID GLAND; THYROXINE;

EID: 84866240086     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947812Y.0000000022     Document Type: Article

References (34)

1. Kim TD, Schwarz M, Nogai H, Grille P, Westermann J, Plockinger U, et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 2010; 11:1209-14.
2. Sternberg CN, Davis ID, Mardiak J. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-8.
3. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, et al. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol. 2010;5:515-9.
4. Shinohara N, Takahashi M, Kamishima T, Ikushima H, Otsuka N, Ishizu A, et al. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. Br J Cancer. 2011;104:241-7.
5. Rogiers A, Wolter P, de Beeck K, Thijs M, Decallonne B, Schoffski P. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? Thyroid. 2010;20:317-22.
6. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors? Thyroid. 2009;19:539-40.
7. Makita N, Miyakawa M, Fujita T, Iiri T. Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid. 2010;20:323-6.
8. Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92:3531-4.
9. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530-40.
10. Lehtonen HJ. Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Fam Cancer. 2011;10(2):397-411.
11. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2009;27:3557-65.
12. Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011;59:526-40.
13. Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol. 2009;6:219-28.
14. Di Fiore F, Rigal O, Ménager C, Michel P, Pfister C. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br J Cancer. 2011;105(12):1811-3.
15. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99:448-54.
16. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145:660-4.
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.
18. Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: A prospective single-center study. Urol Oncol. 2010. Sep 28. [Epub ahead of print].
19. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81-3.
20. Grossmann M, Premaratne E, Desai J, Davis ID. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf). 2008;69:669-72.
21. Sato S, Muraishi K, Tani J, Sasaki Y, Tokubuchi I, Tajiri Y, et al. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J. 2010;57:873-80.
22. Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. 2007;17:351-5.
23. Kappers MH, van Esch JH, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, et al. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab. 2011;96:3087-94.
24. de Groot JW, Zonnenberg BA, Plukker JT, van Der Graaf WT, Links TP. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther. 2005;78:433-8.
25. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794-801.
26. Garfield DH, Wolter P, Schoffski P, Hercbergs A, Davis P. Documentation of thyroid function in clinical studies with sunitinib: why does it matter? J Clin Oncol. 2008;26:5131-2.
27. Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer. 2011;117:534-44.
28. Riesenbeck LM, Bierer S, Hoffmeister I, Kopke T, Papavassilis P, Hertle L, et al. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol. 2011;29(6):807-13.
29. Nelson M, Hercbergs A, Rybicki L, Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006;132:1041-6.
30. Rosner I, Bratslavsky G, Pinto PA, Linehan WM. The clinical implications of the genetics of renal cell carcinoma. Urol Oncol. 2009;27:131-6.
31. Neal J, Wakelee H. AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr Opin Mol Ther. 2010;12:487-95.
32. Hong D, Gordon M, Appleman L, Kurzrock R, Sun Y, Rasmussen E, et al. Interim results from a phase 1b study of safety, pharmacokinetics (PK) and tumor response of the angiopoietin 1/2-neutralizing peptibody AMG 386 in combinations with AMG 706, bevacizumab (B) or sorafenib (S) in advanced solid tumors. Ann Oncol. 2008;19:154.
33. Ronnen EA, Kondagunta GV, Ishill N, Spodek L, Russo P, Reuter V, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006;107(11):2617-21.
34. Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26(1):127-31.